What we do and who we serve.
Atlantic EECP provides Enhanced External Counterpulsation therapy to patients across Florida's east coast — from St. Augustine through Broward County — using the Renew NCP-5, the most advanced portable EECP system currently available. We operate as a mobile service: we bring the equipment to the patient's home, or patients come to our Melbourne, Florida clinic.
Our practice was founded by a patient, not a clinician — Jack Clifford has over 700 hours of personal EECP experience, began with a 100% blocked LAD, and has been running the machine for five years. We operate with clinical oversight and follow standard EECP protocols. We are cash-pay and do not accept insurance assignment, though we provide full documentation for patient self-submission where applicable.
We welcome communication with referring providers. If you have questions about a specific patient's suitability, contraindications, or what the treatment course would look like, call us directly. Most clinical questions get answered in 10–15 minutes.
The machine we use.
- FDA 510(k) clearedCleared for EECP therapy and — uniquely — for improving VO₂ max in healthy patients. The only ECP system with that clearance.
- Real-time EKG gatingInflation and deflation timed to diastole and systole via continuous EKG monitoring. Adjusts automatically to arrhythmia.
- PortableFully portable — we bring it to the patient's home. Same clinical standards as fixed-installation systems.
- Standard protocol35 one-hour sessions. One or two sessions per day. Standard or two-a-day protocol available.
- DocumentationFull treatment summaries provided at course completion for patient records and referring provider review.
The clinical evidence base has expanded well beyond angina.
Chronic Stable Angina
The original and primary indication. EECP is FDA-cleared and Medicare-covered for chronic stable angina. Strong RCT evidence including the MUST-EECP trial. Appropriate for patients with CCS Class II–IV angina who are not candidates for or have failed revascularization.
Ischemic Heart Failure
The PEECH trial demonstrated improvement in exercise duration, quality of life, and NYHA functional class. Appropriate for patients with LVEF ≤35% and NYHA Class II–III symptoms. Contraindicated in decompensated heart failure.
Persistent Symptoms After Revascularization
20–40% of patients continue to have symptoms after stenting or CABG. Microvascular disease and endothelial dysfunction are not addressed by revascularization. EECP targets both. Appropriate 4–6 weeks post-procedure with cardiologist clearance.
Long COVID / Post-Viral Syndrome
Endothelial dysfunction and microvascular injury are central to long COVID pathophysiology. Observational data shows improvement across SF-36 quality-of-life domains. Appropriate for patients with persistent cardiovascular or autonomic symptoms.
Peripheral Artery Disease
EECP improves peripheral circulation and collateral formation. Appropriate for patients with claudication or rest pain who are not candidates for intervention or who have failed conservative management.
Cognitive Decline / Cerebrovascular
Improved cerebral perfusion is a documented effect of EECP. Observational data in early cognitive decline and vascular dementia is promising. Not a primary indication but frequently reported as a secondary benefit.
Diabetic Neuropathy / Microvascular Disease
Improved microvascular circulation and endothelial function are relevant to diabetic neuropathy and retinopathy. Evidence is observational but consistent. Appropriate as adjunctive therapy.
Prevention / Performance Optimization
The Renew NCP-5 carries FDA clearance for improving VO₂ max in healthy patients — the only ECP system with that clearance. Appropriate for patients seeking cardiovascular optimization without a primary cardiac diagnosis.
When EECP is not appropriate.
The following are standard contraindications. We review each patient's history during intake and will decline to treat patients for whom EECP is contraindicated. If you have a patient with a complex history, call us — we can discuss the specifics.
- —Decompensated heart failure (NYHA Class IV with active fluid overload)
- —Significant aortic regurgitation (moderate or severe)
- —Aortic aneurysm
- —Severe peripheral artery disease with active ulceration or gangrene
- —Deep vein thrombosis (active)
- —Phlebitis (active)
- —Severe hypertension (uncontrolled, >180/110)
- —Bleeding diathesis or anticoagulation at therapeutic levels (case-by-case)
- —Pregnancy
- —Atrial fibrillation with rapid ventricular response (rate control required)
- —Recent MI (< 4 weeks)
- —Recent PCI or CABG (< 4–6 weeks)
- —Severe obesity (cuff fit limitations)
- —Significant lower extremity wounds or skin conditions
What you'll receive for your patient's chart.
Pre-treatment intake summary
Patient history review, indication, contraindication screening, and treatment plan — provided before the first session.
Session-by-session log
Date, duration, machine settings, and any patient-reported symptoms for each session. Available on request during the course.
Course completion summary
Full treatment record including total hours, dates, machine used, patient-reported outcomes, and any clinical observations. Provided at course completion.
Provider communication
We will communicate directly with you or your office at any point during the course if clinically relevant observations arise. We are reachable by phone or text.
Send us your patient's information.
Fill out the form and we'll follow up within one business day. For urgent referrals or complex cases, call us directly — we're available seven days a week.
Available seven days a week. Most clinical questions answered in 10–15 minutes.
Jack Clifford's definitive patient guide — the science, the history, the politics, and the practical reality of EECP. The book I wish I'd had in that hospital bed.